Inhaled epinephrine for anaphylaxis

Excitement is building for noninjectable routes of epinephrine, although enthusiasm may briefly wane with the recent Food and Drug Administration announcement that more data will be needed before nasal epinephrine devices can be approved. In addition to nasal routes of epinephrine delivery, evidence for sublingual epinephrine in the treatment of anaphylaxis continues to accumulate, and this product is in the late-stage developmental pipeline.1